Skip to content
DataLookout
Start free
Menu

CAMPERRNCT05366881

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

StatusRecruiting
PhaseNot specified
SponsorAdela, Inc
Primary completion (estimated)

At risk: Primary completion moved at least 9 months later.

See at-risk trials from Adela, Inc

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 13 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Mar 2026 to Dec 31, 2026
    • Study completion pushed from Mar 2027 to Dec 2027
    • Eligibility criteria expanded, about 16 words
    • Site details revised at 13 of 17 sites
  2. Study sites: 15 to 17v13 Show 4 more changesShow less
    • Primary completion date: Sep 2025 to Mar 2026
    • Study completion date: Dec 2026 to Mar 2027
    • Eligibility criteria revised
    • Study description shortened, about 4 words
  3. Lead sponsor: Alzheimer's Disease Expert Lab (ADEL), Inc. to Adela, Incv12
  4. Lead sponsor: Adela, Inc to Alzheimer's Disease Expert Lab (ADEL), Inc.
    • Primary completion date: Dec 2023 to Sep 2025
    • Site details revised at 3 of 15 sites
    v11
  5. Study sites: 8 to 15v10
Show 7 earlier versionsHide 7 earlier versions
  1. Site details revised at 1 of 8 sitesv9
  2. Enrollment target: 5280 to 7000
    • Study title revised
    v8
  3. Study sites: 7 to 8v7
  4. Study sites: 3 to 7v6
  5. Study sites: 2 to 3v5
  6. Site details revised at 1 of 2 sitesv4
  7. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2022 to May 3, 2022
    • Site details revised at 2 of 2 sites
    v3
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Detection of cancer
Timeframe: 24 months

Secondary (3)

Detection of specific cancer types
Tissue of origin
Clinical outcomes

Arms and interventions

Cases

Cases will include participants with newly diagnosed, treatment-naive cancer at the time of enrollment.

Controls

Controls will include participants without known cancer at the time of enrollment.

Sites

17 sites in 1 country